

# Approach to Treatment of Dyspepsia in Primary Care

## A Randomized Trial Comparing “Test-and-Treat” With Prompt Endoscopy

Nicolaas L. A. Arents, MD; Jacob C. Thijs, MD, PhD; Anton A. van Zwet, MD, PhD; Marco Oudkerk Pool, MD, PhD; Jan-Mark Götzt, MD, PhD; Ger T. van de Werf, MD, PhD; Klaas Reenders, MD, PhD; Wim J. Sluiter, MD, PhD; Jan H. Kleibeuker, MD, PhD

**Background:** The value of the “test-and-treat” strategy in the approach to dyspepsia has been evaluated only in a few secondary care studies. Most patients with dyspepsia, however, are treated by their primary care physician. This study evaluated the test-and-treat strategy in primary care.

**Methods:** Patients consulting their general practitioners for dyspepsia were randomized to either direct open-access endoscopy with *Helicobacter pylori* testing or a test-and-treat strategy by *H pylori* serology. In the 12-month follow-up period, any additional treatment or referral for investigations was left at the discretion of the general practitioner. At the end of the study, data were collected concerning the number of endoscopies, changes in symptom severity and quality of life, patient satisfaction, and the use of medical resources.

**Results:** Two hundred seventy patients were enrolled (129 who received endoscopy and 141 in the test-and-

treat group). The prevalence of *H pylori* infection was 38.3% and 37.2% in the test-and-treat and endoscopy groups, respectively. In the test-and-treat group, 46 patients (33%) were referred for endoscopy during follow-up. Improvement in symptom severity, quality of life, and patient satisfaction was comparable in both groups. Patients in the test-and-treat group paid more dyspepsia-related visits to their general practitioner ( $P = .005$ ). Patients in the endoscopy group were more often prescribed proton pump inhibitors ( $P = .007$ ), whereas patients in the test-and-treat group were more often prescribed prokinetic drugs ( $P = .005$ ).

**Conclusions:** The test-and-treat strategy proved to be as effective and safe as prompt endoscopy. Only a minority of patients were referred for endoscopy after the test-and-treat approach.

*Arch Intern Med.* 2003;163:1606-1612

From the Regional Public Health Laboratory, Groningen/Drenthe, the Netherlands (Drs Arents and van Zwet); Department of Gastroenterology, Bethesda Hospital, Hogeveen, the Netherlands (Dr Thijs); Department of Gastroenterology, Isala Clinics, Zwolle, the Netherlands (Dr Oudkerk Pool); Department of Gastroenterology, Wilhelmina Hospital, Assen, the Netherlands (Dr Götzt); and Departments of General Practice (Drs van de Werf and Reenders), Pathology (Dr Sluiter), and Gastroenterology (Dr Kleibeuker), University Hospital, Groningen, the Netherlands.

**I**N PRIMARY CARE, general practitioners (GPs) usually treat younger dyspeptic patients empirically with acid-suppressing agents before considering endoscopy. This approach, in which endoscopy is reserved for patients with persistent symptoms, was asserted to be the most cost-effective strategy by the American College of Physicians in 1985.<sup>1</sup> Since then, however, new data have become available, suggesting that this common practice may have to be reconsidered. First of all, the most common cause of dyspepsia in general practice is functional dyspepsia,<sup>2</sup> and there is no sound evidence to support the use of acid suppression in this condition.<sup>3,4</sup> Second, although peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are initially adequately treated by a course of acid suppression, they usually relapse after discontinuation of the drug.<sup>5-8</sup> Therefore, in most of these patients endoscopy is

merely postponed when the aforementioned approach is followed.<sup>9</sup> Finally, eradication of *Helicobacter pylori* in patients with PUD who harbor this bacterium is far more cost-effective than symptomatic acid-suppressive treatment.<sup>10</sup>

These data have led to the development of several alternative strategies. Some authors proposed a strategy based on non-invasive screening for *H pylori* and referring for endoscopy only patients with positive test results (“test-and-scope”).<sup>11,12</sup> Others have modified this approach and recommended a “test-and-treat” strategy, in which patients who test positive receive anti-*H pylori* treatment, possibly obviating the need for endoscopy.<sup>13-15</sup> On the other hand, it has also been suggested that immediate endoscopy may be the most cost-effective approach.<sup>16,17</sup>

All strategies have been extensively tested by decision-analytic studies,<sup>18-25</sup> but only a few studies have actually compared the different approaches in a clinical

cal setting.<sup>9,13-15,26,27</sup> These clinical studies, however, suffer from one significant drawback. None of them was performed entirely in a primary care setting, where most patients with dyspepsia are treated.<sup>28,29</sup> This article presents the results of a study comparing a test-and-treat strategy with prompt endoscopy. The study was performed entirely in a primary care setting, using open-access endoscopy facilities.

## METHODS

According to the Rome I criteria, dyspepsia was defined as persistent or recurrent pain or discomfort centered in the upper abdomen.<sup>30</sup> Patients consulting any of the 56 participating GPs for dyspepsia were eligible for the study if the GP considered the symptoms severe enough to warrant endoscopy or the prescription of acid-suppressive medication. The GPs were instructed not to include patients with symptoms suggestive of GERD (heartburn or acid regurgitation as the only or predominant symptom). Other exclusion criteria were age younger than 18 years; the presence of sinister<sup>31</sup> symptoms (including the first appearance of dyspeptic symptoms after the age of 55 years); previously documented PUD or GERD; previous surgery of the upper alimentary tract, other than uncomplicated cholecystectomy; previous anti-*H pylori* treatment; the use of proton pump inhibitors (PPIs), bismuth compounds, or antibiotics in the month before inclusion; the use of nonsteroidal anti-inflammatory drugs other than low-dose aspirin in the preceding 2 weeks; known allergy to the drugs used in the study; suspected poor compliance; pregnancy or lactation; and participation in any other study. Patients were withdrawn from the study if any malignancy was diagnosed or if the patient became pregnant. After giving written informed consent, patients were randomized by their GP. Randomization was stratified for each GP by supplying the GP with blocks of 4 sealed envelopes, ensuring 2 patients randomized to the test-and-treat group and 2 patients to the endoscopy group.

In the endoscopy group, the patients were referred for open-access endoscopy, which was performed within 2 weeks after inclusion. At endoscopy, 3 biopsy samples were taken within 2 cm of the pylorus for *H pylori* culture (1 sample) and histologic examination (hematoxylin-eosin staining and either Giemsa staining or immunostaining for *H pylori*) (2 samples). Antibiotic susceptibility for metronidazole (resistant if minimal inhibitory concentration is  $\geq 8$ ) and clarithromycin (resistant if minimum inhibitory concentration is  $\geq 2$ ) was tested by E-test (AB-Biodisk, Solna, Sweden). A venous blood sample was drawn for the detection of anti-*H pylori* IgG antibodies by means of a commercially available assay (Pyloriset EIA-G III; Orion Diagnostica, Espoo, Finland). This assay has shown a sensitivity and specificity of 98.4% and 88.4%, respectively, in a previous study performed in the same region.<sup>32</sup> A peptic ulcer was defined as a mucosal break of greater than 5 mm with a clearly visible ulcer crater in either the stomach or the duodenal bulb. Erosive inflammation of the duodenal bulb was considered to be an appearance of PUD. If PUD was detected at endoscopy, the patient was prescribed ranitidine hydrochloride immediately after endoscopy. Patients with reflux esophagitis were prescribed lansoprazole for a period of 3 months. The dosages were left at the discretion of the endoscopist. In all other cases, the patients were referred back to their GP awaiting culture and histology results. All *H pylori*-infected patients (either culture or histology positive) received a 1-week anti-*H pylori* regimen guided by susceptibility testing: lansoprazole (30 mg twice daily), amoxicillin (1000 mg twice daily), and either metronidazole (500 mg twice daily) if metronidazole sensitive or clarithromycin (500 mg twice daily) if metronidazole resistant. If sus-

ceptibility was not tested, the microorganism was considered metronidazole resistant. In a previous study, performed in the same region,<sup>33</sup> resistance of *H pylori* to clarithromycin was shown to be very rare (about 2%). If a patient had normal endoscopic findings and was *H pylori* negative, cisapride (20 mg twice daily) was prescribed for 4 weeks by the GP according to protocol. Peptic ulcers, erosive gastritis, and erosive duodenitis in the absence of *H pylori* infection were treated after conferring with the gastroenterologist, usually with acid-suppressive agents.

In the test-and-treat group, a venous blood sample was drawn for *H pylori* serologic testing. If results of testing were positive, the patients were prescribed the combination of lansoprazole, amoxicillin, and clarithromycin by the GP. If negative, the GPs were encouraged to prescribe cisapride (20 mg twice daily) for 4 weeks.

After the initial treatment according to protocol, the GP was free to treat the patient according to his or her own insights. This could include a change in treatment; referral for diagnostic tests, including endoscopy; or referral to a gastroenterologist or another specialist.

The patients were followed up for 12 months. At inclusion and at 12 months, the patients were asked to complete a dyspepsia questionnaire evaluating the severity of 8 dyspeptic symptoms (pain in the upper part of the abdomen, bloating, nausea, burping or belching, flatulence, heartburn, sour taste, and halitosis) on a 5-point Likert scale.<sup>34</sup> Quality of life was evaluated at inclusion and after 12 months by means of the RAND-36 questionnaire, a validated Dutch translation of the Short Form-36 questionnaire.<sup>35,36</sup> At 12 months, patients were invited to donate a second blood sample for *H pylori* serologic testing. Successful *H pylori* treatment was defined as a decrease in titer of IgG *H pylori* antibodies of 40% or more.<sup>37</sup> For the detection of a decrease in antibody level, both the entry sample and the 12-month sample were examined in the same run.

Patient satisfaction with medical treatment was evaluated on a 5-point Likert scale. Whenever a patient did not return a questionnaire, he or she was contacted by telephone by one of us (N.L.A.A.) and urged to do so up to 3 times.

At the end of the study, the GPs' records of each patient (electronic and/or patient charts) were reviewed by a single investigator (N.L.A.A.). Data were collected concerning the number of visits for dyspepsia, the number of visits for other reasons, additional investigations (endoscopy, abdominal ultrasound, and x-ray studies of the gastrointestinal tract), specialist referrals, and hospital admissions. Finally, all pharmacies were asked to provide a printed list of all medications delivered to the patients within the 1-year follow-up period. The dyspepsia-related use of medical resources was calculated for medical consultations, dyspepsia-related investigations, hospital admissions, and dyspepsia-related prescriptions.

Differences in mean scores and mean changes in scores between groups were compared after correction for continuity by the method of Yates and Cochran. Mean changes in score within a group were evaluated after correction for continuity by the method of Pitman. Frequencies were compared by the  $\chi^2$  test with Yates correction. Differences in continuous variables between groups were studied by the Mann-Whitney test. All tests were 2-sided, with a level of significance of  $P < .05$ .

The study protocol was approved by the medical ethical committee of the University Hospital Groningen, Groningen, the Netherlands.

## RESULTS

Two hundred eighty-one patients consented to participate in the study (**Figure 1**). Eleven of these patients




Figure 1. Flow diagram of the study patients.

Table 1. Baseline Characteristics of Patients in the Test-and-Treat Group and the Endoscopy Group

	Test-and-Treat Group (n = 141), No. (%)	Endoscopy Group (n = 129), No. (%)	P Value
Median age, y	47	44	.35
Male sex	70 (49.6)	59 (45.7)	.62
Smokers	55 (39.0)	47 (36.4)	.75
Alcohol use (>1 U/d)*	24 (17.0)	22 (17.1)	.87
Born outside the Netherlands	9 (6.4)	6 (4.7)	.72
<i>Helicobacter pylori</i> positive	54 (38.3)	48 (37.2)	.95

\*A unit of alcohol was defined as a standard glass of beer, wine, spirits, etc (approximately 10 g of alcohol).

were not enrolled for the following reasons: failure to return the first questionnaires (n=2), failure to undergo endoscopy (n=4), no biopsy specimens taken at endoscopy (n=2), suspected poor compliance (alcohol abuse [n=1], short stay in the area [n=1]), and presence of sinister symptoms (n=1). Therefore, 270 patients were enrolled, 141 patients in the test-and-treat group and 129 in the endoscopy group. Quality of life, time elapsed since the first appearance of symptoms, and duration of current symptoms were not significantly different between the 2 groups (P ranging between .21 and .98 for all items). The mean score of 1 symptom in the dyspepsia questionnaire (nausea) was significantly higher in the test-and-treat group (2.09 vs 1.79; P=.04). Mean scores of the other symptoms, however, as well as other baseline characteristics (Table 1) were comparable.

Forty-six patients (32.6%) randomized to the test-and-treat group (16 serologically *H pylori* positive) were referred for endoscopy during follow-up. One endos-




Figure 2. Endoscopic diagnoses in the patients in the test-and-treat group referred for endoscopy (n=45) and the endoscopy group (n=129). Because of rounding, percentages may not total 100. N indicates normal or hiatal hernia only; GERD, gastroesophageal reflux disease; DU, duodenal ulcer; EG, erosive gastritis; GC, gastric cancer; and GU, gastric ulcer.

copy was aborted because of lack of cooperation of the patient. The endoscopic diagnoses in the remaining 45 patients as well as in the patients randomized to the endoscopy group are summarized in Figure 2. The endoscopic diagnosis most commonly made in both groups was GERD (test-and-treat group, 31.1%; endoscopy group, 28.7%). The diagnosis of GERD included esophageal erosions (Savary-Miller grade 1 and higher) and/or Barrett metaplasia (n=2). Duodenal ulcer disease (including erosive duodenitis in 4) was found in 1 of the 46 patients in the test-and-treat group and in 10 patients in the endoscopy group (7.8%; 1 patient also had GERD). Gastric ulcer was found in no patient in the test-and-treat group and in 1 patient (0.8%; this patient also had GERD) in the endoscopy group. Erosive gastritis was found in 1 (2.2%) and 3 (2.3%) patients in the test-and-treat and endoscopy groups, respectively. In 3 patients with PUD, both histologic findings and culture were negative for *H pylori*. One of these patients (test-and-treat group) had been treated for *H pylori* infection but still showed erosive inflammation of the duodenal bulb. The other 2 patients, randomized to the endoscopy group, both had a duodenal ulcer. In both, serologic findings were negative as well. The *H pylori* status in all patients who underwent endoscopy is shown in Table 2. In one 54-year-old patient, randomized to the test-and-treat group, a gastric malignancy was diagnosed 3 weeks after inclusion. Further examination showed multiple liver metastases with ascites, and the patient died within 6

**Table 2. *Helicobacter pylori* Status in Patients in the Endoscopy Group and in Patients Who Underwent Endoscopy in the Test-and-Treat Group**

Endoscopic Diagnoses	No. (%) <i>H pylori</i> Positive*	
	Endoscopy Group (n = 129)	Test-and-Treat Group (n = 45)
GERD	12/37 (32)	3/14 (21)
DU	8/10 (80)	1/1 (100)
GU	1/1 (100)	0/0
Erosive gastritis	1/3 (33)	0/0
Gastric malignancy	0/0	1/1 (100)
Normal	26/78 (33)	11/28 (39)

Abbreviations: DU, duodenal ulcer (including erosive duodenitis); GERD, gastroesophageal reflux disease; GU, gastric ulcer.

\*Determined by culture and/or histologic examination in the endoscopy group and by serologic findings at inclusion in the test-and-treat group.


months. In both study groups, endoscopy showed no abnormality or just a hiatal hernia in most patients (62.2% and 60.5% in the test-and-treat and endoscopy groups, respectively). Statistical analysis did not show any significant difference in frequencies of endoscopic diagnoses between the 2 study groups ( $P = .83$ ).

When compared with the biopsy-based detection methods in the endoscopy group (*H pylori* positive when positive on histologic examination and/or culture), the serologic test showed a sensitivity, specificity, and positive and negative predictive value (with 95% confidence intervals) of 86.7% (73.2%-95.0%), 92.5% (84.4%-97.2%), 86.7% (73.2%-95.0%), and 92.5% (84.4%-97.2%), respectively.


Follow-up data were not available for 17 patients (12.1%) in the test-and-treat group and 9 patients (7.0%) in the endoscopy group ( $P = .22$ ) for the following reasons: failure to return follow-up questionnaires ( $n = 22$ ), pregnancy ( $n = 2$ ), and malignancy ( $n = 2$ ) diagnosed during follow-up. Besides the patient with gastric cancer mentioned above, Hodgkin disease was diagnosed in another patient. Baseline characteristics (Table 1) and mean symptom severity score of these dropout patients were comparable to the baseline characteristics of the remaining patients.

Symptom changes in both study groups were evaluated by subtracting the scores in the last questionnaire from the scores in the first questionnaire for each symptom. **Figure 3** shows the mean change for each symptom in both groups. All symptoms improved during the study period, and improvement was comparable in both study groups.

The scores for the quality-of-life categories evaluated by the RAND-36 questionnaire (change in health, general health perception, bodily pain, energy/fatigue, general mental health, role limitations due to personal or emotional problems, role limitations due to physical health problems, social functioning, and physical functioning) were calculated according to the instructions of the questionnaire's designers.<sup>35</sup> To detect any improvement or worsening within a category, the first quality-of-life scores were subtracted from the 12-



**Figure 3.** Mean change in symptom score in the test-and-treat group ( $n = 124$ ) and the endoscopy group ( $n = 120$ ) and the mean difference between both scores, with the 95% confidence interval.



**Figure 4.** Median change in quality-of-life scores in the test-and-treat group ( $n = 124$ ) and the endoscopy group ( $n = 120$ ).

month quality-of-life scores. The median score changes for all categories are shown in **Figure 4**. There was an improvement in most categories in both groups, and the differences between the 2 groups were not statistically significant.

The use of medical resources in each study group is summarized in **Table 3**. The mean number of dyspepsia-related GP visits was significantly higher in the test-and-treat group ( $P = .005$ ). In the endoscopy group, more patients were prescribed PPIs ( $P = .007$ ), making the mean standard daily dosage in this group higher than in the test-and-treat group. The mean standard daily dosage in the patients receiving PPIs, however, was comparable in both groups ( $P = .71$ ). Sixty-eight percent of the patients in the endoscopy group who were prescribed PPIs had endoscopy-proven GERD. Prokinetic drugs were significantly more often prescribed in the test-and-treat group ( $P = .005$ ), making the mean standard daily dosage in this group higher than in the endoscopy group. The use of histamine<sub>2</sub>-receptor antagonists and antacids in both study groups was comparable. In both groups, the same number of patients did not receive any medication for dyspepsia (18.5% and 23.3% for the test-and-treat and endoscopy


**Table 3. Use of Medical Resources in Both Study Groups in the Study Year**

	Mean (25%-75% Interpercentile Range)		Difference	P Value/ OR (95% CI)
	Test-and-Treat Group (n = 124)	Endoscopy Group (n = 120)		
No. of GP visits				
Dyspepsia-related	3.06 (1-4)	2.28 (1-3)	0.78*	.005
Dyspepsia-unrelated	2.73 (1-4)	3.03 (1-5)	-0.30	.38
No. of SDD†				
PPI	28.9 (0-29)	71.0 (0-99)	-42.1*	.007
H <sub>2</sub> RA	22.9 (0-15)	18.8 (0-15)	4.1	.97
Prokinetics	16.0 (0-20)	11.6 (0-5)	4.4*	.005
Antacids	8.1 (0-12)	7.6 (0-12)	0.5	.73
No. of diagnostic tests				
Endoscopy	0.35	1.04	-0.69*	.001
Ultrasonography of upper abdomen	0.14	0.09	0.05	0.6 (0.27-1.41)
Upper GI series	0	0	0	NA
No. of specialist referrals				
Dyspepsia-related	0.05 (0-0)	0.05 (0-0)	0	1.04 (0.32-3.30)
Dyspepsia-unrelated	0.44 (0-1)	0.36 (0-0)	0.08	0.27 (0.43-1.21)
No. of hospital admissions				
Dyspepsia-related	0.01 (0-0)	0.0 (0-0)	-0.01	NA
Dyspepsia-unrelated	0.08 (0-0)	0.08 (0-0)	0	0.92 (0.36-2.36)

Abbreviations: CI, confidence interval; GI, gastrointestinal; GP, general practitioner; H<sub>2</sub>RA, histamine<sub>2</sub>-receptor antagonist; NA, not applicable; OR, odds ratio; PPI, proton pump inhibitor; SDD, standard daily dosage.

\*Significant difference.

†SDD was as follows: lansoprazole, 30 mg; omeprazole, 40 mg; pantoprazole, 40 mg; rabeprazole sodium, 40 mg; ranitidine hydrochloride, 300 mg; cimetidine, 800 mg; famotidine, 40 mg; cisapride, 40 mg; domperidone, 40 mg; metoclopramide hydrochloride, 40 mg; antacid, 2 g.



**Figure 5.** Patient satisfaction in the test-and-treat group (n=124) and the endoscopy group (n=120).

groups, respectively;  $P = .50$ ). Apart from endoscopy, the numbers of dyspepsia-related medical investigations were comparable in both groups ( $P = .34$ ), as was the mean number of specialist referrals for dyspepsia ( $P = .81$ ). Only 1 patient (test-and-treat group) was admitted to the hospital because of upper abdominal symptoms. The use of medical resources for reasons other than dyspepsia was comparable in both groups.

A second serum sample was available in 83 (87%) of 96 *H pylori*-positive patients. According to our definition, anti-*H pylori* treatment had been successful in 39 (87%) of 45 patients in the test-and-treat group and 34 (90%) of 38 in the endoscopy group ( $P = .95$ ).

Patient satisfaction with medical treatment in both groups is shown in **Figure 5**. Most patients (94.4%) were satisfied, and there were no differences between the 2 study groups ( $P = .75$ ).

## COMMENT

This study showed that prompt endoscopy in patients consulting their primary care physician for dyspepsia led to similar symptom resolution, improvement in quality of life, and patient satisfaction as compared with the test-and-treat strategy. More than two thirds of the patients treated according to the test-and-treat strategy were not referred for endoscopy during a follow-up period of 1 year.

To our knowledge, this is the first study comparing the test-and-treat strategy with prompt endoscopy in a primary care setting. As most dyspeptic patients are entirely treated by their GP, the test-and-treat approach should be evaluated in that setting. Lassen et al<sup>15</sup> recently compared the test-and-treat strategy with prompt endoscopy. In that study, however, follow-up was performed completely in a secondary care setting, which may have biased the results. Reassurance and treatment by a gastroenterologist with a special interest in dyspepsia may be more effective than that by a GP, resulting in a decreased use of medical resources and higher patient satisfaction. Our primary care study has several other positive features. After the initial investigation and treatment guidelines, GPs were allowed to treat their patients according to their own insights. Therefore, the outcome of the test-and-treat strategy in our study is presumably very similar to the outcome if a similar approach were followed in daily clinical practice, thus increasing the external validity of the results. Second, all questionnaires regarding symptoms, quality of life, and patient satisfaction were self-administered, avoiding any interpretation bias by the GP. Finally, anti-*H pylori* treatment was prescribed to all *H pylori*-infected patients. Although the

benefit of anti-*H pylori* treatment has been demonstrated unequivocally only in patients with PUD, we aimed to prevent any bias by a possible effect in patients with functional dyspepsia or GERD. Inevitably, our study had some drawbacks. Patients were recruited by their own GPs, which may have introduced a potential selection bias, limiting the comparability between the study patients and the normal dyspeptic population. Moreover, our study does not allow a comparison of the test-and-treat strategy with the currently most often used approach (empirical treatment). We chose to include a control group (prompt endoscopy) rather than an empirical study group, to determine whether the test-and-treat strategy missed any important disease.

We assumed that the abnormalities present in the test-and-treat group at inclusion were similar to the endoscopic findings in the prompt endoscopy group. It should be noted that, in the patients in the test-and-treat group who underwent endoscopy, *H pylori*-positive PUD was not diagnosed. This strongly indicates that the test-and-treat strategy correctly identified all patients with *H pylori*-associated PUD and that these patients received adequate treatment. The only patient in the test-and-treat group in whom PUD was diagnosed had erosive inflammation in the duodenal bulb at endoscopy 6 months after anti-*H pylori* treatment. Endoscopic biopsies excluded *H pylori* infection. Nonsteroidal anti-inflammatory drugs were not prescribed to this patient during the study year, but over-the-counter use cannot be excluded.

The efficacy of the anti-*H pylori* regimen was greater than 85% in both study arms. Susceptibility testing before anti-*H pylori* treatment did not seem to improve the treatment success rate, but this may be related to the low prevalence of clarithromycin resistance in our region. An often-cited argument against the test-and-treat strategy is the possibility of overlooking gastric or esophageal cancer. In our study, gastric cancer was diagnosed in 1 patient 3 weeks after inclusion, which is a duration of delay that has been suggested to be acceptable.<sup>38</sup>

Proton pump inhibitors were more often prescribed in the endoscopy group than in the test-and-treat group. This was most likely related to the prescription of PPIs in nearly all patients with endoscopy-proved GERD, as recommended by the study guidelines, whereas in primary care it is common practice to start treatment with a histamine<sub>2</sub>-receptor antagonist if GERD is expected but not proved. Prokinetics were more often prescribed in the test-and-treat group, which was clearly the direct result of our study protocol advising use of prokinetics in all noninvasively tested *H pylori*-negative patients. Other dyspepsia-related drugs were used equally often in both study groups. Patients in the test-and-treat group more often consulted their GPs for dyspepsia, which may indicate more effective treatment or better reassurance in the endoscopy group. The use of other medical resources, including specialist referrals, hospital admissions, and additional investigations for dyspepsia other than endoscopy, were comparable in both study groups.

Most current guidelines advocate empirical treatment with acid-suppressive agents as a first approach to

dyspepsia. Whether the test-and-treat strategy is more cost-effective than an empirical approach cannot be concluded from this study. One of the most important variables influencing cost-effectiveness of any approach for dyspepsia, however, is the number (and cost) of endoscopies.<sup>18,19</sup> The study by Bytzer et al,<sup>9</sup> comparing an empirical acid-suppressive approach with histamine<sub>2</sub>-receptor antagonist with prompt endoscopy, showed a 34% reduction in the number of endoscopies in the first year. When compared with this outcome, both our study and the study by Lassen et al<sup>15</sup> showed a higher reduction in number of endoscopies (67.4% and 60%, respectively). It could therefore be hypothesized that the test-and-treat approach may be more cost-effective than empirical acid suppression. It should be emphasized, however, that the cost-effectiveness of a test-and-treat strategy largely depends on the prevalence of PUD and *H pylori* infection in the population. The reported declining prevalence of *H pylori* infection has a negative impact on the predictive value of noninvasive tests for *H pylori*. Moreover, the decreasing prevalence of PUD will limit the number of patients most clearly benefiting from anti-*H pylori* treatment.

In conclusion, a test-and-treat approach for dyspeptic patients in primary care is as effective and safe as a strategy in which all patients are immediately referred for endoscopy. Only a minority (33%) of patients are referred for endoscopy after test-and-treat.

Accepted for publication September 16, 2002.

The SENSE (Strategy: Endoscopy vs Serology) study was supported by a grant from Aventis Pharma, Hoevelaken, the Netherlands.

Corresponding author and reprints: Jacob C. Thijs, MD, PhD, Bethesda Hospital, Dr G. H. Amshoffweg 1, 7909 AA Hoogeveen, the Netherlands (e-mail: n.l.a.arents@mmb.aazg.nl).

## REFERENCES

1. Kahn K, Greenfield S, for the Health and Public Policy Committee, American College of Physicians, Philadelphia, Pennsylvania. Endoscopy in the evaluation of dyspepsia. *Ann Intern Med.* 1985;102:266-269.
2. Talley NJ, Silverstein MD, Agraus L, Nyren O, Sonnenberg A, Holtzmann G. AGA technical review: evaluation of dyspepsia. *Gastroenterology.* 1998;114:582-595.
3. Talley NJ. Drug treatment of functional dyspepsia. *Scand J Gastroenterol Suppl.* 1991;182:47-60.
4. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. *Am J Gastroenterol.* 1996;91:660-673.
5. Graham DY, Colon-Pagan J, Morse RS, et al, for the Omeprazole Duodenal Ulcer Study Group. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. *Gastroenterology.* 1992;102:1289-1294.
6. Dammann HG, Walter TA. Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. *Aliment Pharmacol Ther.* 1993;7(suppl 2):17-25.
7. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. *Gastroenterology.* 1988;95:903-912.
8. Koelz HR, Birschler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. *Gastroenterology.* 1986;91:1198-1205.
9. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H<sub>2</sub>-blocker therapy or prompt endoscopy in management of dyspepsia. *Lancet.* 1994;343:811-816.
10. Unger P, Jonsson B, Stalhammar NO. The cost effectiveness of *Helicobacter pylori* eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. *Pharmacoeconomics.* 1995;8:410-427.

11. Sobala GM, Crabtree JE, Pentith JA, et al. Screening dyspepsia by serology to *Helicobacter pylori*. *Lancet*. 1991;338:94-96.
12. Patel P, Khulusi S, Mendall MA, et al. Prospective screening of dyspeptic patients by *Helicobacter pylori* serology. *Lancet*. 1995;346:1315-1318.
13. Heaney A, Collins JSA, Watson RGP, McFarland RJ, Bamford KB, Tham TCK. A prospective randomised trial of a test-and-treat policy versus endoscopy based management in young *Helicobacter pylori* positive patients with ulcer-like dyspepsia, referred to a hospital clinic. *Gut*. 1999;45:186-190.
14. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for *Helicobacter pylori* positive dyspeptic patients in general practice. *Int J Clin Pract*. 1999;53:413-416.
15. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. *Helicobacter pylori* test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. *Lancet*. 2000;356:455-460.
16. Bytzer P. Diagnosing dyspepsia: any controversies left? *Gastroenterology*. 1996;110:302-306.
17. Tytgat G, Hungin APS, Malfertheiner P, et al. Decision-making in dyspepsia: controversies in primary and secondary care. *Eur J Gastroenterol Hepatol*. 1999;11:223-230.
18. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. *Ann Intern Med*. 1995;123:260-268.
19. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for *Helicobacter pylori* for dyspepsia: a decision analysis. *Gastroenterology*. 1996;110:72-83.
20. Sonnenberg A. Cost-benefit analysis of testing for *Helicobacter pylori* in dyspeptic subjects. *Am J Gastroenterol*. 1996;91:1773-1777.
21. Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of *Helicobacter pylori* in management of dyspeptic patients under 45 years of age. *BMJ*. 1996;312:1321-1325.
22. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. *J Fam Pract*. 1997;44:545-555.
23. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for *Helicobacter pylori*-seropositive patients with dyspepsia: clinical and economic consequences. *Ann Intern Med*. 1997;126:280-291.
24. Laheij RJ, Severens JL, Jansen JB, van de Lisdonk EH, Verbeek AL. Management in general practice of patients with persistent dyspepsia: a decision analysis. *J Clin Gastroenterol*. 1997;25:563-567.
25. Olson AD, Deutsch D. Combined empiric treatment and specific *Hp* screening and treatment decrease the cost of evaluating epigastric abdominal pain [abstract]. *Gastroenterology*. 1998;114:A248.
26. Laheij RJ, Severens JL, van de Lisdonk EH, Verbeek AL, Jansen JB. Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. *Aliment Pharmacol Ther*. 1998;12:1249-1256.
27. Duggan A, Elliot C, Tolley K, Whynes D, Hawkey CJ, Logan RF. Randomised controlled trial of four dyspepsia management strategies in primary care with 12 months follow-up [abstract]. *Gastroenterology*. 2000;118:A438.
28. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. *BMJ*. 1989;298:30-32.
29. Muris JWM, Starmans R, Fijten GH, Crebolder HFJM, Krebber TFWA, Knottnerus JA. Abdominal pain in general practice. *Fam Pract*. 1993;10:387-390.
30. Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. *Gastroenterol Int*. 1991;4:145-160.
31. Arents NLA, Thijs JC, Kleibeuker JH. A rational approach to uninvestigated dyspepsia in primary care: review of the literature. *Postgrad Med J*. 2002;78:707-716.
32. Thijs JC, van Zwet AA, Thijs WJ, et al. Diagnostic tests for *Helicobacter pylori*: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. *Am J Gastroenterol*. 1996;91:2125-2129.
33. Arents NLA, van Zwet AA, Thijs JC, Degener JE, Kleibeuker JH. A six-year surveillance of *H. pylori* resistance in a large study population in the Netherlands (n=5946): prevalence of clarithromycin resistance increases, while metronidazole resistance does not increase [abstract]. *Gastroenterology*. 2001;120:A229.
34. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and *Helicobacter pylori* associated gastritis? *J Clin Epidemiol*. 1993;46:273-279.
35. van der Zee KI, Sanderman R, Heyink J. De psychometrische kwaliteiten van de MOS 36-item Short Form Health Survey (SF-36). *Tijdschr Soc Gezondheidsz*. 1993;71:183-191.
36. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. *Med Care*. 1992;30:473-481.
37. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of *Helicobacter pylori*. *Lancet*. 1992;339:893-895.
38. American Gastroenterology Association medical position statement: evaluation of dyspepsia. *Gastroenterology*. 1998;114:579-581.